Biotech Values

[DewDiligence]

Re: Insulin FoB’s

NVO said on its recent Investor Day webcast that FoB’s represent 3-4% of worldwide insulin sales by volume and less than 1% by dollar value. NVO’s executives claim to be utterly unconcerned about losing market share to such competition.

Behind closed doors, however, I would bet that NVO’s executives are more worried than they let on. Until recently, the companies selling insulin FoB’s were flyweights with no reputation to speak of, but now such heavyweights as PFE are involved (#msg-55680051).